Postmarketing Clinical Study on AO-128

Summary

The purpose of open-label study is to evaluate the efficacy and safety of AO-128 (Voglibose) 0.6 mg/day in patients with impaired glucose tolerance (IGT) who had been non-responsive to diet therapy and exercise therapy, and follow up the progress after the end of treatment in patients who was assessed as normoglycemic.

Timeline

Start

2010-03

Primary completion

2012-11

Completion

2012-11

Drugs

Indications